Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Oklahoma Health Sciences Center, 800 NE 10th Street, Oklahoma City, OK 71304, USA.
Gynecol Oncol. 2013 Sep;130(3):411-5. doi: 10.1016/j.ygyno.2013.06.018. Epub 2013 Jun 20.
This study aimed to evaluate the utility of risk stratification of gynecologic oncology patients with neutropenic fever (NF).
A retrospective chart review of gynecologic cancer patients admitted with NF from 2007 to 2011 was performed, wherein demographic, oncologic, and NF characteristics (hospitalization length, complications, and death) were collected. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score was calculated; low risk was considered ≥ 21. SAS 9.2 was used for statistical analyses.
Eighty-three patients met the study criteria. Most (92%) were Caucasian and had advanced stage disease (71%). Primary tumors were 58% ovary, 35% endometrium, and 6% cervix. All patients were receiving chemotherapy on admission (72% for primary, 28% for recurrent disease). Forty-eight percent had a positive culture, and most (58%) positive cultures were urine. Seventy-six percent of patients were considered low risk. High-risk patients were more likely to have a severe complication (10% versus 50%, p=0.0003), multiple severe complications (3% versus 20%, p=0.0278), ICU admission (2% versus 40%, p<0.0001), overall mortality (2% versus 15%, p=0.0417), and death due to neutropenic fever (0% versus 15%, p=0.0124). MASCC had a positive predictive value of 50% and negative predictive value of 90%. The median MASCC score for all patients was 22 (range, 11-26), but the median MASCC score for those with death or a severe complication was 17 (range, 11-24).
Based on this pilot data, MASCC score appears promising in determining suitability for outpatient management of NF in gynecologic oncology patients. Prospective study is ongoing to confirm safety and determine impact on cost.
本研究旨在评估中性粒细胞减少性发热(NF)的妇科肿瘤患者风险分层的效用。
对 2007 年至 2011 年因 NF 住院的妇科癌症患者进行回顾性病历审查,收集人口统计学、肿瘤学和 NF 特征(住院时间、并发症和死亡)。计算多国癌症支持治疗协会(MASCC)风险指数评分;低危被认为≥21 分。使用 SAS 9.2 进行统计分析。
83 名患者符合研究标准。大多数(92%)为白种人,疾病处于晚期(71%)。原发性肿瘤为卵巢 58%、子宫内膜 35%和宫颈 6%。所有患者入院时均接受化疗(原发性疾病 72%,复发性疾病 28%)。48%的患者有阳性培养,大多数(58%)阳性培养为尿液。76%的患者被认为是低危。高危患者更有可能出现严重并发症(10%对 50%,p=0.0003)、多种严重并发症(3%对 20%,p=0.0278)、重症监护病房(ICU)入住(2%对 40%,p<0.0001)、总死亡率(2%对 15%,p=0.0417)和因中性粒细胞减少性发热而死亡(0%对 15%,p=0.0124)。MASCC 的阳性预测值为 50%,阴性预测值为 90%。所有患者的中位 MASCC 评分为 22(范围 11-26),但死亡或严重并发症患者的中位 MASCC 评分为 17(范围 11-24)。
基于这些初步数据,MASCC 评分似乎有望确定妇科肿瘤患者 NF 是否适合门诊管理。正在进行前瞻性研究以确认安全性并确定对成本的影响。